Ultragenyx Pharmaceutical (NASDAQ:RARE) Earns "Overweight" Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE - Free Report) in a research report sent to investors on Tuesday, Benzinga reports. They currently have a $116.00 price target on the biopharmaceutical company's stock.

A number of other research firms have also commented on RARE. Barclays dropped their price target on Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an "overweight" rating on the stock in a research report on Monday, August 5th. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $111.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, July 23rd. The Goldman Sachs Group upped their price target on shares of Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the company a "buy" rating in a report on Friday, August 2nd. Royal Bank of Canada restated an "outperform" rating and set a $77.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Thursday, September 26th. Finally, TD Cowen upped their target price on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a "buy" rating in a research note on Monday. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $88.29.

Ultragenyx Pharmaceutical Trading Up 0.6 %

Shares of NASDAQ:RARE traded up $0.33 during trading on Tuesday, hitting $54.79. 349,986 shares of the company's stock were exchanged, compared to its average volume of 770,489. The firm has a 50-day moving average price of $55.91 and a two-hundred day moving average price of $47.66. Ultragenyx Pharmaceutical has a 1-year low of $31.52 and a 1-year high of $60.37. The firm has a market cap of $5.05 billion, a P/E ratio of -7.51 and a beta of 0.57.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.52) EPS for the quarter, beating analysts' consensus estimates of ($1.64) by $0.12. Ultragenyx Pharmaceutical had a negative return on equity of 266.02% and a negative net margin of 121.57%. The business had revenue of $147.03 million during the quarter, compared to the consensus estimate of $123.20 million. The firm's revenue was up 35.7% on a year-over-year basis. During the same quarter in the prior year, the company posted ($2.25) earnings per share. As a group, research analysts predict that Ultragenyx Pharmaceutical will post -6.28 EPS for the current year.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,465 shares of the stock in a transaction that occurred on Thursday, October 10th. The shares were sold at an average price of $52.76, for a total transaction of $393,853.40. Following the transaction, the chief financial officer now owns 92,301 shares in the company, valued at $4,869,800.76. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $55.85, for a total value of $1,117,000.00. Following the transaction, the chief executive officer now owns 2,223,985 shares in the company, valued at approximately $124,209,562.25. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Howard Horn sold 7,465 shares of the company's stock in a transaction on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total value of $393,853.40. Following the sale, the chief financial officer now owns 92,301 shares of the company's stock, valued at approximately $4,869,800.76. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 47,556 shares of company stock valued at $2,519,367. 5.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Headlands Technologies LLC acquired a new position in Ultragenyx Pharmaceutical during the 1st quarter worth approximately $28,000. nVerses Capital LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the second quarter worth $33,000. UMB Bank n.a. lifted its stake in shares of Ultragenyx Pharmaceutical by 58.1% in the 2nd quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company's stock valued at $39,000 after acquiring an additional 352 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Ultragenyx Pharmaceutical by 622.3% in the 1st quarter. GAMMA Investing LLC now owns 1,004 shares of the biopharmaceutical company's stock valued at $47,000 after acquiring an additional 865 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 67.7% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 3,318 shares of the biopharmaceutical company's stock valued at $155,000 after acquiring an additional 1,339 shares in the last quarter. Institutional investors own 97.67% of the company's stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.